Shionogi's Oral COVID Drug Set For Global Access Through MPP
Hot On Heels Of PIII Data
Executive Summary
Agreement with UN-affiliated body set to expand global availability in lower income countries of Japanese firm’s protease inhibitor, which has faced approval road bumps at home but now looks set to move forward on positive new Phase III data.
You may also be interested in...
Medicines Patent Pool Facilitates Deals With Seven Manufacturers For COVID-19 Antiviral
The Medicines Patent Pool has facilitated sublicenses with seven manufacturers to distribute generic versions of Shionogi’s oral COVID-19 antiviral ensitrelvir across low- and middle-income countries.
MPP Facilitates Agreements With Seven Manufacturers For COVID-19 Antiviral
The Medicines Patent Pool has facilitated sublicenses with seven manufacturers to distribute generic versions of Shionogi’s oral COVID-19 antiviral ensitrelvir across low- and middle-income countries.
New Deals, Modalities In Sights In Japan After Relatively Quiet 2022
After a comparatively subdued 2022 in terms of M&A and other deal-making, a strengthening currency and interest in new areas such as digital tools and cell and gene therapy might see a rebound in activity this year, which should also see domestic approvals of several potential blockbusters and more support for bioventures.